A Phase 1 interventional study of EO2002 and Sham injection in Cataract and Endothelial Cell Loss, Corneal, sponsored by Asociación para Evitar la Ceguera en México. Recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Asociación para Evitar la Ceguera en México · Phase 1, Interventional, and Treatment
The goal of this clinical study is to assess the safety of intracameral injection of EO2002 in subjects post-cataract surgery.
Key Inclusion Criteria:
Exclusion Criteria:
All ocular criteria apply to study eye unless otherwise noted.
EO2002 intracameral injection
Biological: EO2002
EO2002 intracameral injection
Biological: EO2002
EO2002 intracameral injection
Biological: EO2002
Sham injection
Other: Sham injection
Intracameral injection of a single dose of magnetic human corneal endothelial cells (EO2002) either at the time of cataract surgery or post-cataract surgery
Also known as: Magnetic Human Corneal Endothelial Cells
Sham injection
Safety and Tolerability of EO2002
Incidence of Treatment-Emergent Adverse Events
Time frame: 26 weeks
Endothelial Cell Density
Changes in ECD compared to baseline
Time frame: 26 weeks
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Asociación para Evitar la Ceguera en México